You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

SORAfenib

( sor-a-FEN-ib )
Funding:
Exceptional Access Program
  • SORAfenib - Metastatic renal cell carcinoma of clear cell histology as second-line treatment, with specific criteria
  • SORAfenib - Advanced hepatocellular carcinoma, with specific criteria
Other Name(s): Nexavar®
Appearance: tablet

You might also be interested in